About

Marcella Origgi (PhD)

CEO

Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).

Before joining ValoTx, Marcella worked at Johnson & Johnson Innovation, where she was responsible for sourcing external innovation opportunities across oncology, immunology, rare diseases, and ATMPs. Her role involved asset development, due diligence, IP evaluation, public funding landscaping, remote scouting tool evaluation, and partnership development. She also served as a spokesperson at international events and represented J&J Innovative Medicine Italy at Farmindustria Ricerca & Innovazione.

Earlier in her career, Marcella held several roles at Janssen, including as Scientific & Patients Advocacy Groups Manager and as MSL Champion in the Immunology Medical Affairs Department. In these roles, she led and supported medical strategy, clinical trial feasibility, market access planning, and advisory board coordination for therapies including ustekinumab, guselkumab, golimumab, and sirukumab.

Marcella holds a PhD in Biology from the University of Milan, where she attended the Department of Pharmacology and Toxicology. She also holds additional qualifications in Intellectual Property and Trademarks, drug discovery and commercialization, and leadership programmes developed in collaboration with SDA Bocconi and Milan Polytechnic.

Sari Pesonen (PhD)

CSO

Sari Pesonen, Chief Scientific Officer (PhD, co-founder), has held scientific leadership roles in immuno-oncology biotech companies and has vast experience in clinical drug development. She joined Oncos Therapeutics as a Research Director and later took on the role of Head of Clinical Science, leading clinical sample analysis, which for the first time demonstrated the mode of action of oncolytic adenovirus-based cancer immunotherapy. Later, Sari worked as VP Preclinical Research and Clinical Science at Targovax. Sari gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki in a research group focusing on the development of oncolytic viruses for the treatment of cancer. She has supervised 3 PhD students and is a co-author on 60 peer-reviewed research papers.

Harri Jarvelainen (PhD, MBA)

Chief Operating Officer

Dr Harri Järveläinen, Chief Operating Officer, is a pharma industry veteran with a track record of more than 50 development programs – leading preclinical and clinical development, manufacturing, business development, fundraising, and project management. Over the past 20 years, he has held various progressively senior-level roles at large companies such as AstraZeneca, Nestlé, and Pharmaron. Harri Järveläinen has also actively and successfully built and operated several early-stage biotech companies, guiding them from inception to clinical milestones. Recently, he advanced a San Diego-based academic start-up from academia into a clinical-stage biotech, Cend Therapeutics, with the lead oncology product, certepetide, now being tested in multiple mid-to-late-stage clinical trials. Cend went public on Nasdaq as Lisata Therapeutics in September 2022. He earned his Veterinary Medicine and PhD degrees from the University of Helsinki (Finland) and completed postdoctoral training at New York University Medical Center (New York, NY) and the Max Planck Institute (Berlin, Germany). He also holds an MBA from the University of New South Wales (Sydney, Australia) and serves as an Adjunct Professor (Toxicology) at the University of Helsinki. He is the author of over 40 peer-reviewed scientific publications, patents, and book chapters.

Charlotta Backman (M.Sc)

VP Clinical Operations and Regulatory Affairs

Charlotta Backman, VP Clinical Operations and Regulatory Affairs, has a strong background in clinical research with 15 years of experience in the start-up, conduct, and close-out of Phase I to Phase IV clinical trials, mostly including trials in oncology and vaccines. Over the years, she has gained experience from interactions with several regulatory authorities in the EU and in the US. Charlotta worked in the CRO industry for Encorium and Remedium, managing clinical trials in various phases and indications before taking on the responsibility for management of the clinical trials with oncolytic adenoviruses at Oncos Therapeutics (later Targovax). Charlotta has a Master’s degree in Cell Biology from Åbo Akademi University. During her academic career, Charlotta worked as a Researcher and Project Team Leader at the University of Helsinki and Folkhälsan Institute of Genetics in the field of disease genetics.

Petri Priha (Lic.Sc)

VP of CMC

Petri Priha, VP of CMC, has over 20 years’ experience in expert and management positions in vaccine, biopharmaceutical protein, and oncolytic adenovirus process development and GMP manufacturing. Prior to joining Valo Therapeutics in January 2017, Petri served as VP of CMC at Targovax, and before that as Director of Process Development and Quality Assurance at Oncos Therapeutics. During his 5 years at Oncos, he was responsible for the CMC development of an oncolytic adenovirus cancer immunotherapy platform. Petri also served at Ipsat Therapies for 9 years as Director of Production and Quality of prophylactic biopharmaceutical proteins targeted to prevent antibiotic-associated secondary infections. Prior to that, he worked at the National Institute for Health and Welfare, where he was responsible for bacterial vaccine manufacturing. Petri is a chemical engineer (Lic. Sc. Tech.) from Helsinki University of Technology.

Lukasz Kuryk (PhD)

VP Translational and Clinical Science, IP Manager

Lukasz Kuryk, VP Translational and Clinical Science, holds a PhD in biopharmaceutics/oncolytic virotherapy from University of Helsinki, Finland. He also earned his MBA diploma from the Institute of Computer Science PAN, Poland and Woodbury School of Business, UT, USA. Dr Kuryk brings experience in immuno-oncology and immuno-virotherapy, knowledge of preclinical, translational and early-stage clinical drug development in oncology (Phase I and II). Before joining Valo Therapeutics, he worked for last 10 years in clinical stage immuno-oncology companies Targovax (Director, Clinical Science) and Oncos Therapeutics (Research Scientist), on both pre-clinical research and clinical studies utilizing oncolytic vectors and peptide vaccines for cancer treatment. Mr Kuryk also worked at the Institute of Biomedical Research ‘’Alberto Sols’’, Spain, the Military Institute of Hygiene and Epidemiology, Poland. He was also a visiting researcher at the Regional WHO/Europe at the Robert Koch Institute, Germany, Bellvitge Biomedical Research Institute (IDIBELL), Spain, and University of Padova, Italy where conducing numerous research projects in the field of immuno-oncology and virology. Dr Kuryk is an Assistant Professor at the National Institute of Public Health, Poland, being responsible for several research projects in the field of immunotherapy. Lukasz is a Polish citizen and resides in Finland.

Otto Kari (PhD)

VP, Head of Antigen Business Unit

Otto Kari, VP & Head of Antigen Business Unit, holds a Ph.D. in Pharmacy from the University of Helsinki, Finland. He has over 15 years of experience in pharmaceutical research and development, with advanced qualifications in R&D and technology management. During his Ph.D. and post-doctoral studies, he developed and set up novel and innovative methods and infrastructure for the study of biocorona formation on nanotechnological drug delivery systems and viruses. Recently, he served as the Commercial Lead for PeptiCHIP, a microfluidics-based technology for rapid tumor antigen identification developed by Prof. Vincenzo Cerullo’s ImmunoTherapyLab at University of Helsinki.     Previously, Dr Kari has served as a visiting researcher or teacher at the Institute of Environmental Medicine, Karolinska Institutet, Sweden (systems toxicology), and Department of Industrial Engineering and Management, Aalto University, Finland (strategic technology management). He has authored over 13 peer-reviewed articles covering fields such as cancer immunotherapy, pharmaceutical nanotechnology, drug delivery, biophysics, and medical logistics. Dr Kari is also a Laboratory Director for PharmaHUB at the Faculty of Pharmacy, University of Helsinki, and Chairman of the Council at the Finnish Red Cross. 

Leena Ylösmäki (PHD)

VP Preclinical Development

Leena Ylösmäki, Director of Pre-clinical Development, has over 15 years of experience in the fields of basic and applied virology and cancer research. During her academic career, she has studied various different viruses including Influenza A, vaccinia and adenoviruses. Before joining Valo Therapeutics, Leena worked as a PhD researcher at the university of Helsinki where she designed and developed various oncolytic viruses for cancer immunotherapy. Leena earned her PhD in virology from the Faculty of Medicine at the University of Helsinki.

Matthew Vaughan (PhD)

Business Operations Director

Matthew Vaughan, Business Operations Director, gained his PhD in Geology at the University of Otago, New Zealand, in October 2016 while working part-time for the company. His academic research involved the study of microstructural mechanics and velocity anisotropy in deforming ice, and its relationships to the large scale flow of ice sheets. Matthew has completed research exchanges at University College London, Oxford University, and MIT, and has participated in deep field expeditions to the Arctic and Antarctica. During his PhD, he co-supervised several students, lead the construction of two new labs, and helped develop several apparatus for performing low temperature deformation experiments on ice. To date, Matthew is the co-author of seven peer-reviewed research papers and has received funding support from the Royal Society of New Zealand, NASA, and the European Science Foundation. Matthew joined Valo Therapeutics shortly after the company was founded, to assist the team across all aspects of the business.

Philip Stanecki (M.Sc)

Financial Controller

Philip Stanecki, Accounting Manager, holds an M.Sc in Economics and Business Administration (International Business) from Copenhagen Business School. Before joining the Valo Therapeutics team as an Accounting Manager, he worked as an accountant at a licensed accounting office, as well as an auditor at a Big 4 firm in Helsinki. He has been working with listed and large non-listed audit clients over the past few years from a broad range of industries. Philip brings his skills and knowledge in accounting as well as working in an international team from his many years of travel and living abroad.

Joseph Ndika (PhD)

Senior Scientist, Antigen Analytics

Joseph Ndika, Senior Scientist, Antigen Analytics holds a PhD in Clinical Chemistry from Vrije University Medical Center, Amsterdam, Netherlands. Dr Ndika has over 14 years of experience using proteomics (mass spectrometry) and transcriptomics (next generation sequencing, microarrays) profiling of clinical samples to; study perturbation of biological pathways in rare genetic disorders, unravel allergic disease mechanisms and identify diagnostic biomarkers of adverse environmental exposures. Prior to joining Valo Therapeutics, Dr Ndika has worked on projects to develop in vitro assays to study genetic adaptation (FOM-AMOLF, Netherlands), and predict the pathogenicity of novel gene mutations associated with inborn genetic errors of metabolism (VUMC, Netherlands). In the last 6 years, his research activities have been primarily situated at the University of Helsinki, where he optimized/developed liquid chromatography mass spectrometry methods to study nanoparticle-protein interactions, investigate respiratory allergy biomarkers in patient-derived nasal brush/biopsy samples, or identify allergens from biological pesticides. He is co-author on over 27 peer-reviewed publications.

PETRA AHOKAS (M.SC)

Laboratory Manager

Petra Ahokas, Laboratory Manager, has over 10 years of experience working in laboratories, both as a research assistant and as a scientist, mostly in the field of cancer research. She joined Valo Therapeutics in 2018 and was tasked with opening and managing Valo's new research and development laboratory. Before joining Valo Therapeutics, Petra worked in cancer research at the University of Helsinki and extensively with oncolytic viruses as a Research Scientist at Oncos Therapeutics (now Targovax). Prior to that, she worked at the National Public Health Institute of Finland in the Department of Vaccines. Petra has a Master’s degree in Biology from the University of Helsinki.

Hanne Cojoc (M.Sc. Tech)

QA Manager / Technical Scientist

Hanne Cojoc, QA Manager/Technical Scientist, holds an M.Sc. (Tech) in Bioengineering from Tampere University, Finland. She has gained broad QA experience ranging from pharmaceutical development to healthcare technology. Hanne has also extensive experience in bio-technical laboratory work in both the clinical and pre-clinical settings. She has formerly worked at HUSLAB Laboratories in Finland and has vast experience in research environments such as Tampere University and the University of Helsinki's Centre of Excellence in Stem Cell Metabolism (where she conducted her Master’s thesis research).

Suvi Karumo (M.Sc)

Laboratory Scientist, Antigen Business Unit

Suvi Karumo, Laboratory Scientist, holds an M.Sc in Pharmacy from the University of Helsinki with a major in Biopharmacy. Before joining Valo Therapeutics as a Laboratory Scientist in Antigen Business Unit, she has worked as a Research Assistant and Project Researcher in Drug Delivery Group of the University of Helsinki. Her academic work and master’s thesis research involved investigating nanoparticle-mediated drug delivery systems for cancers and eye diseases, with the main focus on liposomal nanocarriers for controlled delivery of peptide-based immunotherapeutic and angiogenesis-inhibiting anticancer drugs.

Sandeep Kumar (PhD)

Research Scientist II

Sandeep Kumar, Research Scientist II, holds a PhD degree in Biochemistry and his academic
research work was focused on drug discovery. He authored several research articles,
reviews and book chapters in peer reviewed journals. After graduation in 2019, he served as
an Assistant Professor of Biochemistry in veterinary research institute in India. In 2020, he
joined as a Research Scientist in Clinical Science department of Targovax, a clinical stage
immuno-oncology company. He was responsible for planning and execution of preclinical
projects on newly constructed adenoviruses. He was also involved in clinical data analysis of
Targovax’s lead clinical candidate, ONCOS-102, a genetically modified oncolytic adenovirus.
He brings his expertise in preclinical and early-stage clinical drug development to Valo.

Kalle Manninen (M.Sc)

Technical Scientist

Kalle Manninen, Technical Scientist, holds an M.Sc. in Pharmacy from the University of Helsinki with a major in Biopharmacy. During his studies he was chosen to the researcher line in the Faculty of Pharmacy, so he has worked as a Research Assistant in several research projects, where most of his professional time was used on utilizing Surface plasmon resonance and Raman spectroscopy in characterization of extracellular vesicles and polymer brushes. Kalle was first introduced to Valo Therapeutics as a seasonal worker to establish an isothermal titration calorimetry method for biophysical characterization of PeptiCRAd complexes, which ultimately ended up being the topic of his master's thesis. Following his graduation he continues developing methods of analysis for elucidating PeptiCRAd properties and complexation. 

David Hinton

Chairman of the Board

David is an experienced executive in the ASX listed environment. He is currently CFO and Company Secretary of Empired Ltd (ASX: EPD) an international IT services provider a position he has held since 2016.  Prior to that he was CFO and Company Secretary of Amcom Telecommunications Ltd (ASX: AMM) since 2008 until taken over by Vocus Communications in 2015. In these positions David has played a key role in the implementation of systems and processes to ensure that financial information is accurate and timely so that commercial decisions can be made in a robust manner. This has enhanced the ability of these two companies to grow in a scalable and sustainable manner. During his time at Amcom it grew from a small ISP in the period, post the de-regulation of the telco industry, to being a true challenger brand by 2015. With the explosion in the demand for data, internet connectivity and Cloud, Amcom built an extensive last mile nationwide fibre network with 10 data centres and developed many adjacent services.  David had a key role in ensuring that the organic and inorganic growth was appropriately funded and that acquisitions were suitably integrated. David also oversaw the legal, compliance and regulatory functions at Amcom a role he also undertakes at Empired. 

David also has extensive corporate experience and has been heavily involved in numerous M&A transactions, IPO’s, and capital and debt raisings. In his role as Company Secretary, he is very familiar with the workings of Boards and governance matters. Prior to 2008, David held senior positions at the diversified industrial Futuris Corporation Ltd and prior to that worked in London and was a Manager at Ernst & Young. He holds a Bachelor of Business degree, is a Fellow of the Institute of Chartered Accountants in Australia and New Zealand, Graduate of the Australian Institute of Company Directors, and a Graduate of the Governance Institute of Australia.

Dr. Andrew Dean

Member of the Board

Dr Andrew Dean, Board Member, completed his medical training in the UK, became a fellow of the Royal Australian College of Physicians in 1993. He established the palliative care services at Sir Charles Gairdner Hospital and St John of God Subiaco in Perth, later becoming professor of palliative medicine at Edith Cowan University Western Australia. In 2001, he founded the health information website virtualmedicalcentre.com earning the Prime Minister award for small business community excellence and a number of other awards. For a number of years this was the busiest health information site of anywhere in Australia. Stepping into medical oncology in 2006, Andrew now is Head of Oncology at St John of God Subiaco Hospital which has the busiest Clinical Trials unit of any private hospital in Western Australia. He also consults at GenesisCare. He has been the principal investigator on numerous studies both national and International, and as such has published extensively relating to his research. He is leading a number of ongoing clinical trials and has set up a charity to fund cancer research into tumours that have traditionally been very poorly funded. He is currently overseeing a number of studies into pancreatic, gastrointestinal and gynaecological cancers. Under his leadership, his hospital, St John of God Subiaco hospital, was awarded the most outstanding site award by the Australasian GastroIntestinal Trials Group at the annual scientific meeting last year. Prior to joining the board, Dr Dean was an independent investor in Valo who instantly saw the need and clinical utility of the Valo suite of products. 

Marcella Origgi (PhD)

CEO

Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).

Before joining ValoTx, Marcella worked at Johnson & Johnson Innovation, where she was responsible for sourcing external innovation opportunities across oncology, immunology, rare diseases, and ATMPs. Her role involved asset development, due diligence, IP evaluation, public funding landscaping, remote scouting tool evaluation, and partnership development. She also served as a spokesperson at international events and represented J&J Innovative Medicine Italy at Farmindustria Ricerca & Innovazione.

Earlier in her career, Marcella held several roles at Janssen, including as Scientific & Patients Advocacy Groups Manager and as MSL Champion in the Immunology Medical Affairs Department. In these roles, she led and supported medical strategy, clinical trial feasibility, market access planning, and advisory board coordination for therapies including ustekinumab, guselkumab, golimumab, and sirukumab.

Marcella holds a PhD in Biology from the University of Milan, where she attended the Department of Pharmacology and Toxicology. She also holds additional qualifications in Intellectual Property and Trademarks, drug discovery and commercialization, and leadership programmes developed in collaboration with SDA Bocconi and Milan Polytechnic.

Dr. Paul Porter

Member of the Board

Associate Professor Paul Porter (MBBS, FRACP), Director, is the founder of Freeman Road Pty Ltd, an Australian company that specialises in early stage biomedical investments with an emphasis on global research and development collaborations. Freeman Road has investments in companies across Australia, South East Asia, Europe and the USA.

Paul is an experienced medical researcher, lecturer, director of training and paediatric physician at two major paediatric hospitals in Western Australia. He leads an established a research unit specialising in novel biometric diagnostic technology and algorithm development, with active programs targeting respiratory disease, antenatal care and mental health disorders in children and adolescents. He is the Chair of the Ramsay Health Care Human Research and Ethics Committee for Western and South Australia.

He is passionate about supporting advances in healthcare in the developing world.

Prof. Vincenzo Cerullo

Chairman of the Valo Tx Scientific and Clinical Advisory Board

Prof. Vincenzo Cerullo (Vince), Scientific Founder, is a Professor in Biological Drug Development, Head of the Drug Research Program and a HiLIFE Fellow, Translational Immunology Programme at the University of Helsinki.

Vince gained his PhD at the Centre for Genetic Engineering (CENIGE) at the University of Naples, Federico II in 2004. He then moved to Houston Texas (USA), where he completed a Postdoc at the Baylor College of Medicine. Later, he moved to the University of Helsinki and in 2012 was awarded a tenure-track professorship, opening the ImmunoViroTherapy Lab. IVTLab has raised more than 5 million Euros for research, including the prestigious ERC Consolidator Grant, the HiLIFE Fellowship and the Jane and Aatos Erkko Foundation grant. Vince received the Outstanding Young Investigator award in 2014 from the European Society of Gene and Cell Therapy, as well as the Excellence in Research Award from the American Society of Gene and Cell Therapy in 2015.

One of Vince’s passion is science dissemination. He has been involved from the beginning in the organisation of the Science Track at the Slush conference in Helsinki. Vince pitched on the Slush stage in 2015 and 2016 and on the Slush Y Science stage in 2017 (www.slush.org). Among others, he has presented a TEDx talk on the importance of creativity in science (https://youtu.be/1btbElPnREI ).

Prof. Paolo Antonio Ascierto

Member of the Scientific and Clinical Advisory Board

Prof. Paolo Antonio Ascierto is a world-leading key opinion leader in melanoma disease and immunotherapy. He is currently Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute “Pascale” in Naples, Italy. He is Editorial Board Member, Editor and Scientific Reviewer for leading medical journals and a member of the Steering Committee of the Society of Melanoma Research (SMR). Dr Ascierto is part of the Board of Directors for the Society of ImmunoTherapy of Cancer (SITC) and of the Cancer Development Drug Forum (CDDF), and is President of the Fondazione Melanoma Onlus, and the Campania Society of ImmunoTherapy of Cancer (SCITO). He has been an invited speaker to over 400 national and international scientific meetings, courses, and workshops. He has presided as Principle Investigator on over 150 clinical trials, and he is the author of over 600 publications in peer-reviewed journals. His awards and honours are numerous and include receiving the GEF Health Award in 2022. He has received funding from the POR FESR and ERA-NET, among others.

Dr Jeffrey Bockman

Member of the Scientific and Clinical Advisory Board

Dr Jeffrey Bockman received a BA from the University of California at San Diego, an MA in English/Creative Writing from New York University, and a PhD in Medical Microbiology from the University of California at Berkeley. He is the Executive Vice President, Head of Oncology at Lumanity BioConsulting, and was an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr Sidney Altman, on ribozymes, and Dr Stanley Prusiner, on prions. He brings to the SAB extensive commercial and strategic perspective on the pharmaceutical and biotech industries, including leading the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories. He is a frequent speaker at industry events such as BIO on the intersection of scientific, clinical, and strategic issues affecting biotech oncology drug development. Jeff is a member of AACR, ASCO, ASH, ASGCT, SITC and NYAS. He is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, a member of the Advisory Group to Skipper Bio Med, and is on the Clinical Advisory Board of ImmunOS (Zurich) and the Scientific Advisory Board of hC Bioscience (Cambridge, MA).

Prof. Malcolm K. Brenner

Member of the Scientific and Clinical Advisory Board

Prof. Malcom K. Brenner is an award-winning physician-scientist who has pioneered the therapeutic use in cancer of T cell immunologic approaches and genetic engineering strategies.  He is the Founding Director, Centre for Cell and Gene Therapy, Baylor College of Medicine (BCM), Houston Methodist Hospital and Texas Children’s Hospital. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy and of the International Society for Cell Therapy. Dr Brenner obtained his medical degrees and PhD from the University of Cambridge, England. Dr Brenner’s work has been funded by the NIH-NCI, the Leukemia and Lymphoma Society, the Cancer Prevention and Research Institute of Texas, and several charitable foundations. He has been involved in the foundation of several companies, such as Allovir, Marker Therapeutics, and Tessa Therapeutics.

Prof. Kevin Harrington

Member of the Scientific and Clinical Advisory Board

Prof. Kevin Harrington qualified in medicine from the University of London and obtained his PhD from Imperial College, London. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists. He completed postgraduate training in clinical oncology (Royal College of Radiologists Rohan Williams medallist) and postdoctoral research in Professor Richard Vile’s laboratory at the Molecular Medicine Programme in the Mayo Clinic. He subsequently was appointed to a group leader position at The Institute of Cancer Research (ICR), London and an honorary consultant oncologist post at the Royal Marsden Hospital (RMH). He is the Head of the Division of Radiotherapy and Imaging at the ICR, and Director of the CRUK ICR/RMH RadNet Centre of Excellence. He has led phase I, II and III trials of oncolytic virotherapies, immunotherapy and radiation-drug combinations. He brings to the SAB a longstanding focus on gene therapy and viral gene therapy as ways to selectively destroy cancer cells and activate anti-tumour immune responses. His laboratory research focuses on the use of biologically targeted agents, in combination with treatments such as radiotherapy and chemotherapy, to target cancer cells selectively, especially in head and neck cancer and in melanoma.